Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 7/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11330327 | 0.83 | IMPDH2 (0.60) | IMPDH2NPSR1POLBMAPK1SMN1; SMN2 | |
| SCHEMBL20754232 | 0.83 | IMPDH2 (0.50) | IMPDH2MEN1KMT2A | |
| SCHEMBL7827237 | 0.82 | NPSR1 (0.55) | IMPDH2NPSR1POLBFFAR1LMNA | |
| SCHEMBL490437 | 0.79 | CYP3A4 (0.56) | IMPDH2NPSR1POLBMEN1KMT2A | |
| SCHEMBL30871956 | 0.79 | CYP3A4 (0.56) | IMPDH2NPSR1POLBMEN1KMT2A | |
| SCHEMBL490551 | 0.79 | CYP1A2 (0.61) | IMPDH2NPSR1POLBMAPK1SMN1; SMN2 | |
| SCHEMBL7813393 | 0.78 | POLB (0.51) | NPSR1POLB | |
| SCHEMBL11331668 | 0.78 | TAAR1 (0.59) | IMPDH2NPSR1POLBFFAR1 | |
| SCHEMBL3675317 | 0.77 | ALOX5 (0.51) | IMPDH2NPSR1FFAR1MEN1KMT2A | |
| SCHEMBL7523213 | 0.77 | NPSR1 (0.55) | IMPDH2NPSR1POLBFFAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| CN-115109116-A | Preparation and use of active oxygen scavenger derivatives | 凯瑞康宁生物工程（武汉）有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-111278807-B | Preparation and use of active oxygen scavenger derivatives | 凯瑞康宁生物工程（武汉）有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3668837-B1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPHARMA LTD (KY) | 2022-07-06 | — | — | EP | disclosed |
| EP-3668837-B1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPHARMA LTD (KY) | 2022-07-06 | — | — | EP | disclosed |
| US-20210047367-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPharma Ltd. (KY) | 2021-02-18 | — | — | US | disclosed |
| US-20210047367-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPharma Ltd. (KY) | 2021-02-18 | — | — | US | disclosed |
| US-10858394-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XW LABORATORIES INC. (KY) | 2020-12-08 | — | — | US | disclosed |
| US-10858394-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | XW LABORATORIES INC. (KY) | 2020-12-08 | — | — | US | disclosed |
| CN-111278807-A | Preparation and use of active oxygen scavenger derivatives | 凯瑞康宁生物工程（武汉）有限公司 | 2020-06-12 | — | — | CN | disclosed |
| US-20200181194-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPharma Ltd. (KY) | 2020-06-11 | — | — | US | disclosed |
| US-20200181194-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XWPharma Ltd. (KY) | 2020-06-11 | — | — | US | disclosed |
| WO-2019033330-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | XW LABORATORIES, INC. (CN) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181194-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | AIFM2, GPX1, GPX4 | IMPDH2 1961/4885NPSR1 926/4885POLB 2848/4885 |
| US-20210047367-A1 | PREPARATION AND USES OF REACTIVE OXYGEN SPECIES SCAVENGER DERIVATIVES | AIFM2, GPX1, GPX4 | IMPDH2 1961/4885NPSR1 926/4885POLB 2848/4885 |
| US-11692008-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | AIFM2, GPX1, GPX4 | IMPDH2 1961/4885NPSR1 926/4885POLB 2848/4885 |
| US-10858394-B2 | Preparation and uses of reactive oxygen species scavenger derivatives | AIFM2, GPX1, GPX4 | IMPDH2 1961/4885NPSR1 926/4885POLB 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.